# PREVENT (OverC in people without symptoms)

Source: https://onco.cc/trials/prevent-overc/  
OnCo record `prevent-overc` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Chinese study of about 12,500 people without symptoms that gives them Burning Rock's OverC blood test and follows up positive results.

## Summary

PREVENT (NCT05227534) is a single-arm interventional study sponsored by Guangzhou Burning Rock Dx Co., Ltd with West China Hospital. It evaluates the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 12,500 participants, a start on 1 June 2022 and primary completion expected on 1 March 2024.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Also known as: PREVENT
- Registry id: NCT05227534
- Phase: not-applicable
- Setting: Adults without symptoms but with cancer risk in China, tested with the OverC multi-cancer detection blood test with diagnostic follow-up
- Sponsor: Guangzhou Burning Rock Dx Co., Ltd. with West China Hospital
- Enrolled: 12500

## Sources

- ClinicalTrials.gov NCT05227534: https://clinicaltrials.gov/study/NCT05227534

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- drugs: [OverC Multi-Cancer Detection Blood Test](https://onco.cc/drugs/overc-mcdbt/)
- companies: [Burning Rock Biotech](https://onco.cc/companies/burning-rock/)

---
JSON: https://onco.cc/api/v1/entities/prevent-overc.json